CVS Health CorpCVSTOP PICKAug 31, 2016Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)
For some reason, this is being pressured along with the rest of the healthcare space simply because of the potential regulatory changes that may be revised. Even if they do, this company is one of those great business models that is both combined Retail/Pharma as well as Pharma Benefit Management. It has great margins relative to its peer group. Also, demographics are really promising. 8% of the consumer wallet is spent on healthcare, and that is going to be growing to north of 14%-15% in the years ahead. Dividend yield of 1.82%.